BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12875987)

  • 1. Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
    Behrmann I; Wallner S; Komyod W; Heinrich PC; Schuierer M; Buettner R; Bosserhoff AK
    Am J Pathol; 2003 Aug; 163(2):683-90. PubMed ID: 12875987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.
    Hellerbrand C; Mühlbauer M; Wallner S; Schuierer M; Behrmann I; Bataille F; Weiss T; Schölmerich J; Bosserhoff AK
    Carcinogenesis; 2006 Jan; 27(1):64-72. PubMed ID: 16081515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
    García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
    Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.
    Chen ZH; Zhang H; Savarese TM
    Cancer Res; 1996 Mar; 56(5):1083-90. PubMed ID: 8640765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
    Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
    Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
    Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients.
    Miyazaki S; Nishioka J; Shiraishi T; Matsumine A; Uchida A; Nobori T
    Int J Oncol; 2007 Nov; 31(5):1069-76. PubMed ID: 17912432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
    Wild PJ; Meyer S; Bataille F; Woenckhaus M; Ameres M; Vogt T; Landthaler M; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
    Arch Dermatol; 2006 Apr; 142(4):471-6. PubMed ID: 16618867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
    Kim J; Kim MA; Min SY; Jee CD; Lee HE; Kim WH
    Genes Chromosomes Cancer; 2011 Jun; 50(6):421-33. PubMed ID: 21412930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A potential predictive marker for response to interferon in malignant melanoma.
    Wild PJ; Meyer S; Landthaler M; Hofstaedter F; Bosserhoff AK
    J Dtsch Dermatol Ges; 2007 Jun; 5(6):456-9. PubMed ID: 17537037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
    Marcé S; Balagué O; Colomo L; Martinez A; Höller S; Villamor N; Bosch F; Ott G; Rosenwald A; Leoni L; Esteller M; Fraga MF; Montserrat E; Colomer D; Campo E
    Clin Cancer Res; 2006 Jun; 12(12):3754-61. PubMed ID: 16778103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
    Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
    Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
    Christopher SA; Diegelman P; Porter CW; Kruger WD
    Cancer Res; 2002 Nov; 62(22):6639-44. PubMed ID: 12438261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin.
    Bataille F; Rogler G; Modes K; Poser I; Schuierer M; Dietmaier W; Ruemmele P; Mühlbauer M; Wallner S; Hellerbrand C; Bosserhoff AK
    Lab Invest; 2005 Jan; 85(1):124-36. PubMed ID: 15492751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia.
    Bertin R; Acquaviva C; Mirebeau D; Guidal-Giroux C; Vilmer E; Cavé H
    Genes Chromosomes Cancer; 2003 May; 37(1):44-57. PubMed ID: 12661005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of EphB6 expression in metastatic melanoma.
    Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
    Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.